Skip to content
Peptide research

ARA-290

Also known as Cibinetide
Category
Immune & Defense
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

An erythropoietin-derived peptide engineered to spur nerve and tissue repair without raising red blood cell counts, marketed for neuropathic pain and diabetic metabolic support. Evidence rests on Phase 2 trials showing gains in nerve density, pain, and HbA1c, but no Phase 3 data exists and long-term safety is unknown. One trial had serious adverse events including an unrelated death, and non-trial supply is unregulated. Not FDA-approved; banned by WADA.

Read Full record

Studied uses & evidence

Studied uses(8)

  • Regenerates small nerve fibers, shown as increased corneal nerve fiber area in a Phase 2 trial

    Medium

    Small placebo-controlled trial found increased corneal nerve fiber area at 4 mg dose in sarcoidosis patients.

  • Reduces neuropathic pain — significant improvements in PainDetect and SFNSL scores in both sarcoidosis and diabetic neuropathy patients

    Medium

    Human trials show pain score gains, but the largest trial's effect missed significance.

  • Improves metabolic control — significant reductions in HbA1c (p=0.002), cholesterol/HDL ratio (p=0.039), and triglycerides (p=0.043) in diabetic patients

    Medium

    Single small trial found improved HbA1c, cholesterol ratio, and triglycerides in diabetics.

Evidence limits

Evidence Level
Early Clinical (Phase I/II)

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(8)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Not approved by any regulatory agency — quality and purity of non-clinical-trial sources cannot be guaranteed

    High
  • Prohibited by WADA — use may result in anti-doping violations for competitive athletes

    High
  • Investigational compound — long-term safety profile not established; no Phase 3 data available

    High
  • Serious adverse events in Phase 2 diabetes trial: 4 SAEs including 1 renal insufficiency event (possibly related) and 1 fatal myocardial infarction (judged unrelated by safety committee)

    Moderate
  • No long-term carcinogenicity or reproductive toxicity data available

    Moderate
  • Potential immune modulation effects — caution advised when combining with immunosuppressants or biologic anti-inflammatory drugs

    Theoretical
  • Injection site reactions (mild) reported in clinical trials

    Theoretical
  • Headache reported as a common mild adverse event

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.